Halogen atoms in the modern medicinal chemistry: hints for the drug design.
暂无分享,去创建一个
Marcelo Zaldini Hernandes | M. Hernandes | S. M. Cavalcanti | D. Moreira | W. F. de Azevedo Júnior | A. Leite | Ana Cristina Lima Leite | Suellen Melo T Cavalcanti | Diogo Rodrigo M Moreira | Walter Filgueira de Azevedo Junior | S. Cavalcanti | W. F. de Azevedo Junior
[1] M. Shimaoka,et al. Crystal structure of isoflurane bound to integrin LFA‐1 supports a unified mechanism of volatile anesthetic action in the immune and central nervous systems , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[2] Gianni Chessari,et al. From fragment to clinical candidate--a historical perspective. , 2009, Drug discovery today.
[3] Jennifer M. Adler,et al. Crystal Structure of Iodotyrosine Deiodinase, a Novel Flavoprotein Responsible for Iodide Salvage in Thyroid Glands* , 2009, The Journal of Biological Chemistry.
[4] Nahid M. Yazdani,et al. Discovery of inducible nitric oxide synthase (iNOS) inhibitor development candidate KD7332, part 1: Identification of a novel, potent, and selective series of quinolinone iNOS dimerization inhibitors that are orally active in rodent pain models. , 2009, Journal of medicinal chemistry.
[5] Yong-Jun Jiang,et al. Ab initio calculations on halogen‐bonded complexes and comparison with density functional methods , 2009, J. Comput. Chem..
[6] Zhihai Liu,et al. Comparative Assessment of Scoring Functions on a Diverse Test Set , 2009, J. Chem. Inf. Model..
[7] Stefan Güssregen,et al. Evidence for C-Cl/C-Br...pi interactions as an important contribution to protein-ligand binding affinity. , 2009, Angewandte Chemie.
[8] Yiannis N Kaznessis,et al. Path-integral method for predicting relative binding affinities of protein-ligand complexes. , 2009, Journal of the American Chemical Society.
[9] D. Herschlag,et al. Evaluating the potential for halogen bonding in the oxyanion hole of ketosteroid isomerase using unnatural amino acid mutagenesis. , 2009, ACS chemical biology.
[10] Jean-Luc Wolfender,et al. Modern approaches in the search for new lead antiparasitic compounds from higher plants. , 2009, Current drug targets.
[11] R. D. dos Santos,et al. Early toxicity screening and selection of lead compounds for parasitic diseases. , 2009, Current drug targets.
[12] Ettore Novellino,et al. Exploiting the pyrazolo[3,4-d]pyrimidin-4-one ring system as a useful template to obtain potent adenosine deaminase inhibitors. , 2009, Journal of medicinal chemistry.
[13] Brian W Matthews,et al. Halogenated benzenes bound within a non-polar cavity in T4 lysozyme provide examples of I...S and I...Se halogen-bonding. , 2009, Journal of molecular biology.
[14] G. Candiani,et al. Assessing the Bioisosterism of the Trifluoromethyl Group with a Protease Probe , 2009, ChemMedChem.
[15] F. Diederich,et al. Pentafluorosulfanyl as a Novel Building Block for Enzyme Inhibitors: Trypanothione Reductase Inhibition and Antiprotozoal Activities of Diarylamines , 2009, Chembiochem : a European journal of chemical biology.
[16] Jongki Hong,et al. Cytotoxic bromotyrosine derivatives from a two-sponge association of Jaspis sp. and Poecillastra sp. , 2008, Bioorganic & medicinal chemistry letters.
[17] M. Shimaoka,et al. The volatile anesthetic isoflurane perturbs conformational activation of integrin LFA‐1 by binding to the allosteric regulatory cavity , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[18] Adnan Memic,et al. How Do Halogen Substituents Contribute to Protein‐Binding Interactions? A Thermodynamic Study of Peptide Ligands with Diverse Aryl Halides , 2008, Chembiochem : a European journal of chemical biology.
[19] P. Metrangolo,et al. Halogen Versus Hydrogen , 2008, Science.
[20] Pierangelo Metrangolo,et al. Halogen bonding in supramolecular chemistry. , 2008, Angewandte Chemie.
[21] Adrian Whitty,et al. Cooperativity and biological complexity. , 2008, Nature chemical biology.
[22] W. Hagmann,et al. The many roles for fluorine in medicinal chemistry. , 2008, Journal of medicinal chemistry.
[23] Vladimir V Poroikov,et al. Computer-aided discovery of anti-inflammatory thiazolidinones with dual cyclooxygenase/lipoxygenase inhibition. , 2008, Journal of medicinal chemistry.
[24] Jan Schultz,et al. Integration of fragment screening and library design. , 2007, Drug discovery today.
[25] Y. Shishido,et al. Synthesis of aromatic compounds containing a 1,1-dialkyl-2-trifluoromethyl group, a bioisostere of the tert-alkyl moiety. , 2007, Bioorganic & medicinal chemistry letters.
[26] M. Soares,et al. Synthesis, Cruzain Docking, and in vitro Studies of Aryl‐4‐Oxothiazolylhydrazones Against Trypanosoma cruzi , 2007, ChemMedChem.
[27] P Voth Regier Andrea and Ho Shing,et al. The role of halogen bonding in inhibitor recognition and binding by protein kinases. , 2007 .
[28] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[29] Peter Politzer,et al. Molecular surface electrostatic potentials and anesthetic activity , 2007, Journal of molecular modeling.
[30] G. V. Paolini,et al. Global mapping of pharmacological space , 2006, Nature Biotechnology.
[31] G. Klebe. Virtual ligand screening: strategies, perspectives and limitations , 2006, Drug Discovery Today.
[32] Hisayoshi Kobayashi,et al. Diastereomers of dibromo-7-epi-10-deacetylcephalomannine: crowded and cytotoxic taxanes exhibit halogen bonds. , 2006, Journal of medicinal chemistry.
[33] S. Wonnacott,et al. From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research. , 2005, Drug discovery today.
[34] Christophe Meyer,et al. Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains. , 2005, Journal of medicinal chemistry.
[35] B. Orser,et al. Emerging molecular mechanisms of general anesthetic action. , 2005, Trends in pharmacological sciences.
[36] Pierangelo Metrangolo,et al. Halogen bonding based recognition processes: a world parallel to hydrogen bonding. , 2005, Accounts of chemical research.
[37] Jin Kwan Kim,et al. Biarylcarboxybenzamide derivatives as potent vanilloid receptor (VR1) antagonistic ligands. , 2005, Bioorganic & medicinal chemistry letters.
[38] Eric Westhof,et al. Halogen bonds in biological molecules. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[39] Kelly Chibale,et al. Synthesis and structure-activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and Trypanosoma cruzi. , 2004, Journal of medicinal chemistry.
[40] Grégori Gerebtzoff,et al. Halogenation of Drugs Enhances Membrane Binding and Permeation , 2004, Chembiochem : a European journal of chemical biology.
[41] Justin C. Biffinger,et al. The Polar Hydrophobicity of Fluorinated Compounds , 2004, Chembiochem : a European journal of chemical biology.
[42] Dmytro M. Havaleshko,et al. Isoflurane Pretreatment Supports Hemodynamics and Leukocyte Rolling Velocities in Rat Mesentery During Lipopolysaccharide-Induced Inflammation , 2004, Anesthesia and analgesia.
[43] M. Berthelot,et al. Halogen-bond geometry: a crystallographic database investigation of dihalogen complexes. , 2003, Acta crystallographica. Section B, Structural science.
[44] H. Kubinyi. Drug research: myths, hype and reality , 2003, Nature Reviews Drug Discovery.
[45] David J Newman,et al. Natural products as sources of new drugs over the period 1981-2002. , 2003, Journal of natural products.
[46] A. Gołębiowski,et al. Lead compounds discovered from libraries: part 2. , 2003, Current opinion in chemical biology.
[47] Renxiao Wang,et al. Comparative evaluation of 11 scoring functions for molecular docking. , 2003, Journal of medicinal chemistry.
[48] F. Canduri,et al. Molecular model of cyclin-dependent kinase 5 complexed with roscovitine. , 2002, Biochemical and biophysical research communications.
[49] Y. Martin,et al. Do structurally similar molecules have similar biological activity? , 2002, Journal of medicinal chemistry.
[50] Stephen R. Johnson,et al. Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.
[51] W. F. de Azevedo,et al. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. , 2002, Biochemical and biophysical research communications.
[52] Tudor I. Oprea,et al. Is There a Difference between Leads and Drugs? A Historical Perspective , 2001, J. Chem. Inf. Comput. Sci..
[53] P. Metrangolo,et al. Halogen bonding: a paradigm in supramolecular chemistry. , 2001, Chemistry.
[54] P. Wardman. Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. , 2001, Current medicinal chemistry.
[55] E. Eger,et al. Neither GABAA nor Strychnine-Sensitive Glycine Receptors Are the Sole Mediators of MAC for Isoflurane , 2001, Anesthesia and analgesia.
[56] M Pastor,et al. VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[57] P. Selzer,et al. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.
[58] V. Hruby,et al. The effect of halogenation on blood–brain barrier permeability of a novel peptide drug☆ , 1999, Peptides.
[59] John M. Barnard,et al. Chemical Similarity Searching , 1998, J. Chem. Inf. Comput. Sci..
[60] E. Sausville,et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts. , 1998, Blood.
[61] E. Eger,et al. Minimum Alveolar Anesthetic Concentration Values for the Enantiomers of Isoflurane Differ Minimally , 1997, Anesthesia and analgesia.
[62] Robin Taylor,et al. Hydrogen bonding of carbonyl, ether, and ester oxygen atoms with alkanol hydroxyl groups , 1997, J. Comput. Chem..
[63] J. Tocher. Reductive activation of nitroheterocyclic compounds. , 1997, General pharmacology.
[64] H. Maehr. Combinatorial chemistry in drug research from a new vantage point. , 1997, Bioorganic & medicinal chemistry.
[65] S H Kim,et al. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. , 1997, European journal of biochemistry.
[66] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .
[67] Frank H. Allen,et al. The Nature and Geometry of Intermolecular Interactions between Halogens and Oxygen or Nitrogen , 1996 .
[68] S H Kim,et al. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[69] L. Povirk,et al. DNA damage and mutagenesis induced by nitrogen mustards. , 1994, Mutation research.
[70] R. Dickinson,et al. Can the stereoselective effects of the anesthetic isoflurane be accounted for by lipid solubility? , 1994, Biophysical journal.
[71] T. Connick,et al. Fluorine-19 nuclear magnetic resonance studies of binary and ternary complexes of thymidylate synthase utilizing a fluorine-labeled folate analogue. , 1993, Biochemistry.
[72] W. R. Lieb,et al. Stereospecific effects of inhalational general anesthetic optical isomers on nerve ion channels. , 1991, Science.
[73] J. Rossjohn,et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. , 2006, Blood.
[74] L. M. Lima,et al. Bioisosterism: a useful strategy for molecular modification and drug design. , 2005, Current medicinal chemistry.
[75] N. Hrib. The dopamine D4 receptor: A controversial therapeutic target , 2000 .
[76] M. Schlosser,et al. About the “physiological size” of fluorine substituents: Comparison of sensorially active compounds with fluorine and methyl substituted analogues , 1996 .